Federal Register / Vol. 82, No. 176 / Wednesday, September 13, 2017 / Notices 43025 

Prevention, and the Agency for Toxic 

Substances and Disease Registry. 

Claudette Grant, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2017–19444 Filed 9–12–17; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: Grant Reviewer 

Recruitment and Recordkeeping. 

Title: Case Plan Requirement, Title 

IV–E of the Social Security Act. 

OMB No.: 0970–0428. 

Respondents: State and Tribe title IV– 

B and title IV–E agencies. 

Description: Under section 471(a)(16) 

of title IV–E of the Social Security Act 

(the Act), to be eligible for payments, 

states and tribes must have an approved 

title IV–E plan that provides for the 

development of a case plan for each 

child for whom the State or Tribe 

receives foster care maintenance 

payments and that provides a case 

review system that meets the 

requirements in section 475(5) and 

475(6) of the Act. 

The case review system assures that 

each child has a case plan designed to 

achieve placement in a safe setting that 

is the least restrictive (most family-like) 

setting available and in close proximity 

to the child’s parental home, consistent 

with the best interest and special needs 

of the child. Through these 

requirements, States and Tribes also 

comply, in part, with title IV–B section 

422(b) of the Act, which assures certain 

protections for children in foster care. 

The case plan is a written document 

that provides a narrative description of 

the child-specific program of care. 

Federal regulations at 45 CFR 1356.21(g) 

and section 475(1) of the Act delineate 

the specific information that should be 

addressed in the case plan. The 

Administration for Children and 

Families (ACF) does not specify a 

recordkeeping format for the case plan 

nor does ACF require submission of the 

document to the Federal government. 

Case plan information is recorded in a 

format developed and maintained by the 

State or Tribal child welfare agency. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Case Plan ........................................................................................................ 544,098 1 4.80 2,626,436 

Estimated Total Annual Burden 

Hours: 2,626,436. 

In compliance with the requirements 

of the Paperwork Reduction Act of 1995 

(Pub. L. 104–13, 44 U.S.C. Chap 35), the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information may be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Planning, Research 

and Evaluation, 330 C Street SW., 

Washington, DC 20201. Attn: ACF 

Reports Clearance Officer. Email 

address: infocollection@acf.hhs.gov. All 

requests should be identified by the title 

of the information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2017–19367 Filed 9–12–17; 8:45 am] 

BILLING CODE 4184–25–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–D–5297] 

Microdose Radiopharmaceutical 

Diagnostic Drugs: Nonclinical Study 

Recommendations; Draft Guidance for 

Industry; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a draft 

guidance for industry entitled 

‘‘Microdose Radiopharmaceutical 

Diagnostic Drugs: Nonclinical Study 

Recommendations.’’ This draft guidance 

is intended to assist developers of 

microdose radiopharmaceutical 

diagnostic drugs on the nonclinical 

studies recommended to support human 

clinical trials and marketing 

authorization. The draft guidance 

discusses how to refine nonclinical 

study recommendations for this class of 

drug given its unique characteristics. 

This draft guidance is intended to 

provide recommendations for a pathway 

to full drug development (marketing 

authorization) for microdose 

radiopharmaceutical diagnostic drugs. 

DATES: Submit either electronic or 

written comments on the draft guidance 

by November 13, 2017 to ensure that the 

Agency considers your comment on this 

draft guidance before it begins work on 

the final version of the guidance. 

ADDRESSES: You may submit comments 

on any guidance at any time as follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 


sradovich on DSK3GMQ082PROD with NOTICES